Form 4: Verve Therapeutics Director Michael MacLean Granted Stock Options as Part of Compensation

Verve Therapeutics, Inc. Director Michael F. MacLean was granted 42,200 stock options with an exercise price of $5.73, vesting over one year or upon the next annual meeting, as part of the company's 2021 Stock Incentive Plan.

Summary

• Michael F. MacLean, a Director of Verve Therapeutics, Inc. (VERV), acquired 42,200 stock options on June 5, 2025.
• The stock options have an exercise price of $5.73 per share.
• These options were issued under the company's 2021 Stock Incentive Plan as part of its director compensation program.
• The vesting commencement date is the grant date, June 5, 2025.
• All shares underlying the option will vest upon the earlier of the one-year anniversary of the vesting commencement date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. MacLean's continued service as a director.
• The options have an expiration date of June 4, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates standard corporate governance and incentive alignment for a director, which is generally viewed favorably by investors. It's a routine transaction, not indicative of significant positive or negative news.

Positives

• The grant of stock options aligns the interests of Director Michael F. MacLean with those of the shareholders, incentivizing long-term value creation.
• This is a standard practice for director compensation, indicating a structured approach to governance and incentive alignment.

Future Outlook

The stock options granted to Director MacLean are subject to a vesting schedule, with full vesting expected by the earlier of June 5, 2026, or prior to the company's first annual meeting of stockholders after the grant date, contingent on his continued service.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and high-growth sectors, to attract and retain talent, and to align leadership incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology industry, comparable to compensation structures seen at companies like CRISPR Therapeutics AG (CRSP) or Editas Medicine, Inc. (EDIT), which also utilize equity-based incentives for their board members.
• The vesting schedule, typically over one year or tied to the next annual meeting, is also a common approach to ensure continued service and commitment from directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Michael F. MacLean by Verve Therapeutics, Inc. constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from aligned director incentives.
• Director (Michael F. MacLean): Receives equity-based compensation, incentivizing performance and long-term commitment to the company.

Next Steps

• The stock options will vest upon the earlier of the one-year anniversary of the grant date (June 5, 2025) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Key Dates

Keywords

Verve Therapeutics, VERV, Form 4, Stock Option, Director Compensation, Insider Transaction, Equity Incentive Plan, Beneficial Ownership